CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results
2023 · Nature Medicine · 152 citations
https://doi.org/10.1038/s41591-023-02404-6
A
Ana Alarcón Tomás
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
94
Papers
2.0K
Citations
20
h-index
25
i10-index
Ana Alarcón Tomás is an academic researcher from Hospital Sant Joan de Déu Barcelona. The author has contributed to research in topics: CAR-T cell therapy research & Lymphoma Diagnosis and Treatment & Hematopoietic Stem Cell Transplantation. The author has an h-index of 20, co-authored 80 publications.
ORCID: 0000-0002-6290-1061Papers by this author
worksHow I treat adverse effects of CAR-T cell therapy
2020 · ESMO Open · 41 citations
https://doi.org/10.1136/esmoopen-2020-000746
Conventional and novel [18F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma
2024 · Journal of Hematology & Oncology · 31 citations
https://doi.org/10.1186/s13045-024-01540-x
An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma
2025 · Nature Medicine · 29 citations
https://doi.org/10.1038/s41591-025-03532-x
Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma
2022 · Transplantation and Cellular Therapy · 8 citations
https://doi.org/10.1016/j.jtct.2022.08.001
Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy
2024 · Haematologica · 4 citations
https://doi.org/10.3324/haematol.2024.286021
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat